Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.
Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.
复制标题
DOI：
10.1016/j.semarthrit.2022.151987
复制
发表时间：
2022-08
影响因子：
5
通讯作者：
Kayser C
中科院分区：
文献类型：
--
作者：
de Oliveira SM;Martins LVO;Lupino-Assad AP;Medeiros-Ribeiro AC;de Moraes DA;Del-Rio APT;Oliveira MC;Sampaio-Barros PD;Kayser C
新冠肺炎可能与系统性硬化症(SSc)患者的更严重程度和死亡率有关。本研究旨在评估新冠肺炎在巴西SSc患者队列中的患病率、严重性和死亡率。这项多中心、回顾性、观察性研究包括2020年3月至2021年6月期间在S的四个中心跟踪调查的1,042名SSc患者。新冠肺炎的诊断是通过适当的阳性RT-PCR检测或高度可疑的感染来确定的。将患者分为轻度(门诊治疗，不需要氧气支持)和中至重度(住院和/或需要氧气支持)新冠肺炎。在1,042名SSc患者中，118名患者被诊断为新冠肺炎。间质性肺疾病(SSc-ILD)在总队列中的发生率为65.6%，在合并新冠肺炎的SSc患者中为46.3%。轻度新冠肺炎78例(66.1%)，中重度40例(33.9%)，死亡6例(5.1%)。单因素分析显示，肺动脉高压(OR9.50，p=0.006)、SSc-ILD(OR3.90，p=0.007)、FVC和Lt；80%(OR2.90，p=0.007)、心脏受累(OR5.53，p=0.003)、利妥昔单抗的使用(OR3.92，p=0.039)是新冠肺炎预后不良的危险因素。多因素分析显示，只有SSc-ILD与中重度新冠肺炎的发病风险显著相关(OR2.73，95%CI1.12~6.69，p=0.02)。40%的患者在出现新冠肺炎后仍有症状，主要是呼吸困难和/或咳嗽(17%)。在这组SSc患者中，那些患有SSc-ILD的患者受到新冠肺炎的高度影响，具有中到重度新冠肺炎感染和死亡的更高风险。
COVID-19 may be associated with greater severity and mortality in patients with systemic sclerosis (SSc). The present study aimed to evaluate the prevalence, severity and mortality of COVID-19 in a Brazilian cohort of SSc patients. This multicenter, retrospective, observational study included 1,042 SSc patients followed in four centers of São Paulo between March 2020 and June 2021. Diagnosis of COVID-19 was established by proper positive RT-PCR testing or by highly suspicious infection. Patients were grouped into mild (outpatient setting treatment and no need for oxygen support) and moderate-to-severe (hospitalization and/or need for oxygen support) COVID-19. Of the 1,042 SSc patients, 118 patients were diagnosed with COVID-19. Interstitial lung disease (SSc-ILD) was present in 65.6% of the total cohort and in 46.3% of SSc patients with COVID-19. There were 78 (66.1%) cases of mild COVID-19, and 40 (33.9%) cases of moderate-to-severe disease, with 6 (5.1%) deaths. By univariate analysis, pulmonary arterial hypertension (OR 9.50, p=0.006), SSc-ILD (OR 3.90, p=0.007), FVC <80% (OR 2.90, p=0.01), cardiac involvement (OR 5.53, p=0.003), and use of rituximab (OR 3.92, p=0.039), but not age, gender, comorbidities or use of corticosteroids, were predictors of worse outcome for COVID-19. Using multivariate analysis, only SSc-ILD was significantly associated to a higher risk of moderate-to-severe COVID-19 (OR 2.73, 95% CI 1.12-6.69, p=0.02). Forty percent of the patients remained with symptoms after presenting COVID-19, predominantly dyspnea and/or cough (17%). In this cohort of patients with SSc, those with SSc-ILD were highly impacted by COVID-19, with a higher risk of moderate-to-severe COVID-19 infection and death.
登录
查看更多内容
DOI：
10.1016/s2665-9913(21)00222-8
发表时间：
2021-11
期刊：
The Lancet. Rheumatology
影响因子：
--
作者：
Boekel L;Steenhuis M;Hooijberg F;Besten YR;van Kempen ZLE;Kummer LY;van Dam KPJ;Stalman EW;Vogelzang EH;Cristianawati O;Keijzer S;Vidarsson G;Voskuyl AE;Wieske L;Eftimov F;van Vollenhoven R;Kuijpers TW;van Ham SM;Tas SW;Killestein J;Boers M;Nurmohamed MT;Rispens T;Wolbink G
通讯作者：
Wolbink G
DOI：
10.15557/pimr.2020.0003
发表时间：
2020-01-01
影响因子：
3.6
作者：
通讯作者：
--
DOI：
10.1164/rccm.202007-2794oc
发表时间：
2020-12-15
影响因子：
24.7
作者：
Drake TM;Docherty AB;Harrison EM;Quint JK;Adamali H;Agnew S;Babu S;Barber CM;Barratt S;Bendstrup E;Bianchi S;Villegas DC;Chaudhuri N;Chua F;Coker R;Chang W;Crawshaw A;Crowley LE;Dosanjh D;Fiddler CA;Forrest IA;George PM;Gibbons MA;Groom K;Haney S;Hart SP;Heiden E;Henry M;Ho LP;Hoyles RK;Hutchinson J;Hurley K;Jones M;Jones S;Kokosi M;Kreuter M;MacKay LS;Mahendran S;Margaritopoulos G;Molina-Molina M;Molyneaux PL;O'Brien A;O'Reilly K;Packham A;Parfrey H;Poletti V;Porter JC;Renzoni E;Rivera-Ortega P;Russell AM;Saini G;Spencer LG;Stella GM;Stone H;Sturney S;Thickett D;Thillai M;Wallis T;Ward K;Wells AU;West A;Wickremasinghe M;Woodhead F;Hearson G;Howard L;Baillie JK;Openshaw PJM;Semple MG;Stewart I;Jenkins RG;ISARIC4C Investigators
通讯作者：
ISARIC4C Investigators
影响因子：
2.3
作者：
Henrique-Neto, Álvaro;Vasconcelos, Marianna Yumi Kawashima;Oliveira, Maria Carolina
通讯作者：
Oliveira, Maria Carolina
影响因子：
8.4
作者：
Amzat, Jimoh;Aminu, Kafayat;Danjibo, Maryann C.
通讯作者：
Danjibo, Maryann C.